DAPA-CKD 蛋白组学新见解:达格列净调控肾脏结局相关通路
该研究对 DAPA-CKD 试验中 2485 例 CKD 患者进行血浆蛋白组学分析,鉴定与复合肾脏结局相关的蛋白和通路,并评估达格列净治疗 12 个月后的调控作用。结果显示达格列净改变了 216 种蛋白及 137 条肾脏结局相关通路中的 35 条,涉及细胞外基质重塑、炎症纤维化和免疫血管交互,支持其抗炎抗纤维化潜力。
要点
- 达格列净治疗 12 个月后校正安慰剂效应,改变 216 种血浆蛋白,其中 KIM-1 降幅最大(-14.9%)。
- 与肾脏结局相关的 137 条通路中,35 条(25%)被达格列净调控。
- 被调控通路主要涉及细胞外基质重塑、炎症与纤维化及免疫血管交互。
核心结论
- 达格列净可调控与 CKD 进展相关的关键通路,支持其抗炎和抗纤维化潜力。
研究设计与样本
- 基于 DAPA-CKD 试验的蛋白组学分析,纳入 4304 例中 2485 例(57.7%)CKD 患者。
主要发现
- 与复合肾脏结局最强相关的通路为肝纤维化、IGF 转运调节和 TNF 信号通路。
- 达格列净治疗 12 个月后校正安慰剂效应,改变 216 种蛋白,KIM-1 降幅最大(-14.9%,95%CI -17.9 至 -11.7)。
- 137 条与肾脏结局相关的通路中,35 条(25%)被达格列净调控,其中 11 条(31%)活性下降、10 条(29%)活性增加。
关键数值与推荐
- 纳入患者 eGFR 25-75 mL/min/1.73m2,尿白蛋白肌酐比 200-5000 mg/g。
- 复合肾脏结局定义为 eGFR 下降 50%、肾衰竭和肾脏死亡。
临床怎么用
- 蛋白组学提示达格列净通过调控炎症和纤维化通路延缓 CKD 进展,可辅助理解其肾脏保护机制。
局限性
- 仅覆盖 57.7% 的 DAPA-CKD 患者,蛋白组学发现需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Dapagliflozin improves kidney outcomes in patients with chronic kidney disease (CKD), yet the underlying mechanisms by which it exerts protective effects are not fully elucidated. Here, we applied plasma proteomics to identify proteins and pathways linked to CKD progression and examined which of these are modulated by dapagliflozin. METHODS: We measured 3072 circulating plasma proteins (Olink, Uppsala, Sweden) in 2485 of the 4304 (57.7%) patients with CKD from the DAPA-CKD trial (eGFR 25-75 mL/min per 1.73 m2 and urinary albumin-to-creatinine ratio 200-5000 mg/g). Proteins associated with the composite kidney outcome (50% eGFR decline, kidney failure, and kidney death) and with dapagliflozin treatment were respectively identified by multivariable Cox proportional hazard regression and ANCOVA. Ingenuity pathway analysis was used to identify relevant molecular pathways and upstream regulators. RESULTS: Pathways that had the strongest association with the composite kidney outcome were hepatic fibrosis, insulin-like growth factor transport regulation, and tumor necrosis factor signaling. These pathways were generally related to fibrosis and inflammation. After 12 months, dapagliflozin treatment showed a (placebo-corrected) modification of 216 proteins, of which kidney injury molecule-1 showed the strongest reduction (-14.9%; 95% confidence interval: -17.9, -11.7). Of the 137 pathways associated with the kidney outcome, 35 (25%) were modified by dapagliflozin. Among these, activity of 11 (31% of 35) pathways decreased, and 10 (29% of 35) pathways were increased. Pathways associated with kidney outcome and modulated by dapagliflozin were related to extracellular matrix remodeling, inflammation and fibrosis, and immune-vascular interactions. CONCLUSIONS: This proteomic analysis reveals mechanisms underlying dapagliflozin's beneficial effects in CKD progression and shows that key pathways associated with CKD progression are modified by dapagliflozin, supporting its anti-inflammatory and antifibrotic potential.
引用
- de la Rambelje MA, Jongs N, Greasley PJ, et al. New insights from DAPA-CKD indicate that dapagliflozin modulates key pathways related to kidney outcomes. Kidney Int. 2026. PMID: 42508612. doi:10.1016/j.kint.2026.06.043
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。